Health technology assessment (HTA) can be used to make healthcare systems more
equitable and efficient. Advances in precision oncology are challenging conventional …

Treating disease according to precision health requires the individualization of therapeutic
solutions as a cardinal step that is part of a process that typically depends on multiple …

Liquid biopsy (LB) is a minimally invasive method which aims to detect circulating tumor-
derived components in body fluids. It provides an alternative to current cancer screening …

Background: The global alliance for genomics and healthcare facilities provides innovative
solutions to expedite research and clinical practices for complex and incurable health …

Promising drug development efforts may frequently fail due to unintended adverse reactions.
Several methods have been developed to analyze such data, aiming to improve …

Background Single‐arm trials are common in precision oncology. Owing to the lack of
randomized counterfactual, resultant data are not amenable to comparative outcomes …

Personalized management of diseases by considering relevant patient features enables
optimal treatment, instead of management according to an average patient. Precision …

Introduction Next-generation sequencing (NGS) identifies genetic variants to inform
personalized treatment plans. Insufficient evidence of cost-effectiveness impedes the …

Causing a fifth of all disease burden in the region1, the incidence of cancer across Europe
has increased from around two million to three million cases since the end of the last decade …

Background Biomarker-guided therapy in an experimental setting has been suggested to
improve patient outcomes. However, trial-specific pre-screening tests are time and tissue …